Targeted therapies have greatly improved clinical outcomes and reshaped the treatment standards for patients with genomic alterations in EGFR, ALK, ROS1, NTRK, etc. The response rate to EGFR inhibitors (EGFRis) is approximately 70% in patients with EGFR mutations,1,2 who account for 15–40% of patients with non-small cell lung cancer (NSCLC). The gene discussed is ALK; the disease is non-small cell lung carcinoma.